Cortechs.

Vasa Therapeutics announced that the U.S.

Cymbiotika will launch its supplements in all Tar

A new era for consumer longevity begins – unit

Minovia Therapeutics said that the U.S.

McGill study shows digital cognitive exercises c

A new survey reveals how concern, confusion and

Cumulus announced that it presented multiple stud

Alzheon announced the peer-reviewed publication o

Partnership with Twin Health combines AI-powered

Smart ring maker valued at $11bn after doubling

Buck Institute team shows that reducing glycatio

Global Life Science Market Analyst Anastasia Bys

Clinique La Prairie is launching its CLP Holistic

Clinique La Prairie is launching its CLP Holistic

Roche’s test measures levels of pTau181 in pla

New clinical data strengthen the case for the ‘longevity amino acid’ as scientists map its role in protecting brain function and aging cells. Ergothioneine – an amino acid found in mushrooms, beans and oat bran – has long intrigued researchers for its antioxidant and cytoprotective properties. Humans cannot synthesize it, but we actively transport and store it through a dedicated mechanism, suggesting evolutionary importance, and lower circulating levels have been linked with cognitive decline and neurodegenerative disease. Now, evidence from one of the the first placebo-controlled trials assessing cognitive performance in healthy adults has brought ergothioneine into sharper focus. Conducted by Zajac et al, the study examined whether daily supplementation with pure ergothioneine could influence cognitive outcomes in healthy older adults (55–79 years) with subjective memory complaints. While modest in scale, the findings mark a shift from correlation to intervention – from observing associations in plasma levels to testing measurable effects on brain function. Longevity.Technology: Ergothioneine has been the quiet achiever of the antioxidant world – a molecule long admired in mechanistic studies, but rarely tested where it really matters: in healthy humans. The arrival of cognitive data from a placebo-controlled trial is not just a scientific footnote; rather, it…

Genflow Biosciences PLC has provided an update on

Facility at NUS Medicine targets precision gerom

Annovis Bio’s buntanetap found to reduce infla

U.S.

Annovis announced that new biomarker analyses fro

Serotonin Anti-Aging Centers has inaugurated a ne

TruDiagnostic has been awarded a Small Business I

Alterity Therapeutics has disclosed positive find

Biomodal has launched a Certified Service Provide

FDA approval of Stealth’s mitochondria-targete

Collaboration aims to connect AI diagnostics, pe

AI-generated predictive biomarkers enable early

CND Life Sciences has announced that the U.S.

New analysis finds marked acceleration in longev

New funding signals growing seriousness in pet l

Allegro NV, a biomedical company developing nanot

Telomir Pharmaceuticals has announced new preclin

Form Bio and Cure Rare Disease have entered a str

NeuroSense Therapeutics Ltd.

Serina Therapeutics, a clinical-stage biotechnolo

BlueRock Therapeutics says that its Phase I trial

Fractyl Health has revealed preclinical results f

Manjit Sareen reflects on the first Asia-Pacific

Vaccine selectively targets toxic forms of amylo

Harness Therapeutics has unveiled its second-gene

Algen Biotechnologies is combining CRISPR and AI

Algen Biotechnologies is combining CRISPR and AI

At LIC 2025, investors, scientists and founders

The DripBar, an intravenous vitamin therapy franc

The DripBar, an intravenous vitamin therapy franc

Evelyne Bischof on cognition, biomarkers and the

Cirrus Therapeutics lands seed funding to advanc

Klotho Neurosciences today announced it has signe